Thed rug-eluting stents (DES)with biodegradable polymers has minimized the complications as compared to the first-generation DES. The purpose of this large-scale, non-randomized, retrospective study was to evaluate the outcomes of various DES in the real-world patients at 18-month follow-up. The application of DES, including biodegradable-polymer sirolimus-eluting stents(SES) (Metafor- Meril Life Sciences Pvt.Ltd., India or Yukon Choice Flex (YCF)- Translumina Therapeutics LLP, Indiaor Relisys Medical Devices Ltd, India) and everolimus-eluting stents (EES)(Tetrilimus- Sahajan and Medical Technologies Pvt. Ltd., Surat, India) in treatment of patients with CAD has achieved great success. This study sought to evaluate the clinical outcomes of various DES in real-world patients who underwent PCI for CAD at 18-month follow-up.

A total of 2010 consecutive patients who underwent percutaneous coronary intervention for coronary artery disease were included in the study. Out of 2010, 981 patients were implanted with Yukon Choice Flex (YCF), 500 with Tetrilimus, 304 with Metafor and 225 with Premier stents. The clinical endpoint of the study was the incidence of major adverse cardiac events (MACE), composite of cardiac death, myocardial infarction (MI), and ischemia-driven target lesion revascularization (ID-TLR), at 18-month follow-up after the index procedure.

The mean age of 2010 enrolled patients was 56.58 ± 11.52years and 1525 (75.87%) were male. The average length of stents used was 23.14 ± 8.52 mm, 25.89 ± 10.34mm, 26.03 ± 9.88 mm, and 23.71 ± 7.58 mm (P=0.52), and the average stent diameter was 2.99 ± 0.41 mm, 2.98 ± 0.38 mm, 2.93 ± 0.37 mm, and 3.06 ± 0.43 mm of Premier, Metafor, Tetrilimus, and YCF stents, respectively. The total incidence of MACE at 18-month follow-up was 7 (3.11%), 5 (1.6%),8 (1.6%) and 24 (2.5%) (P=0.58) for Premier, Metafor, Tetrilimus, and YCF stents, respectively. Stent thrombosis incidence was 2 (0.89 %), 0 (0.0%), 0 (0.0 %), and 2 (0.20 %) (P=0.12) in Premier, Metafor, Tetrilimus,and YCF stents, respectively.

Real-world patients in the current study treated with different newer-generation drug-eluting stents came across similar rates of MACE and ST at 18-months follow-up.